Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.22.00179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concomitant Usage of H1-Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival.
Cancer Med
January 2025
Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.
Purpose: Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1-antihistamine use is associated with improved overall survival in patients with lung and skin cancers receiving immunotherapy. Therefore, we retrospectively evaluated the impacts of H1-antihistamine use in cancer patients during immunotherapy.
View Article and Find Full Text PDFData mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.
BMC Pharmacol Toxicol
December 2024
Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Background: H1-antihistamines are widely used to treat symptoms depending on histamine release in a variety of conditions. However, neurological adverse events have been reported in post-marketing surveillance studies and there are limited literatures comparing the neurological disorders associated with newer-generation H1-antihistamines from real-world datasets.
Aims: We performed a comparative analysis of nervous system disorders and several newer-generation H1-antihistamines including: cetirizine, loratadine, levocetirizine, desloratadine and fexofenadine.
Mortality in adult patients with chronic spontaneous urticaria: A real world cohort study.
J Allergy Clin Immunol
December 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
Background: Chronic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life-limiting, but the mortality of CSU has not been investigated.
Objective: To assess all-cause mortality in CSU patients, risk for comorbidities that are leading causes of death and impact of guideline-recommended urticaria treatments on mortality rates.
Methods: This is a retrospective population-based cohort study of electronic health records of 272,190 adult CSU patients and 12,728,913 non-urticaria controls from the US Collaborative TriNetx Analytics Network.
Objective: To assess the efficacy of combining acupuncture with pricking blood therapy to treat chronic spontaneous urticaria (CSU) and compare its outcomes with those of second-generation H1-antihistamines.
Methods: Seventy CSU patients were enrolled and randomly assigned to receive treatment with either oral loratadine tablets or a combination of acupuncture and pricking blood therapy (n=35 each). Evaluations were conducted at baseline, at the conclusion of the 4-week treatment period, and at the 4th and 8th weeks post-treatment time points.
Association of concomitant H1 antihistamine and immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer: a cohort study.
Transl Lung Cancer Res
October 2024
Department of Immunology and Biotherapy, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Article Synopsis
- A study investigated the effects of short-term use of antihistamines alongside immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer to see if it improved treatment efficacy and reduced immune-related side effects.
- The research analyzed 211 patient records, dividing them into two groups: 109 patients who received H1 antihistamines during ICI treatment and 102 who did not.
- Results showed significantly better median progression-free survival (12.7 months vs. 4.3 months) and overall survival (32.8 months vs. 18.1 months) in the experimental group, suggesting that H1 antihistamines may be beneficial as a complementary treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!